Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Knockdown Of Mtdh Increases Drug Sensitivity To Hdac Inhibitor And Trail Combination Treatment In Endometrial Cancer Cells, Xiangbing Meng, Pavla Brachova, Shujie Yang, Zhi Xiong, Yuping Zhang, Kimberly Leslie
Knockdown Of Mtdh Increases Drug Sensitivity To Hdac Inhibitor And Trail Combination Treatment In Endometrial Cancer Cells, Xiangbing Meng, Pavla Brachova, Shujie Yang, Zhi Xiong, Yuping Zhang, Kimberly Leslie
Xiangbing Meng
Understanding the molecular mechanisms of chemoresistance is vital to design therapies to restore chemosensitivity. MTDH mediates drug resistance by regulating expression of genes required for the control of apoptosis and cell cycle. These findings indicate that sensitivity to chemotherapy agents and combination treatment with HDAC inhibitor and TRAIL can be restored by manipulating MTDH, and hence depletion of MTDH is a potentially novel avenue for effective cancer therapy.
The Combination Of Paclitaxel And Gefitinib Inhibits Endometrial Cancer Cells By Inducing Mitotic Catastrophe: Proof Of Principle For Dual Therapy In Endometrial Cancer, Xiangbing Meng, Laura Laidler, Lina Albitar, Anna Holmes, Donghai Dai, Thomas Buekers, David Bender, Kimberly Leslie
The Combination Of Paclitaxel And Gefitinib Inhibits Endometrial Cancer Cells By Inducing Mitotic Catastrophe: Proof Of Principle For Dual Therapy In Endometrial Cancer, Xiangbing Meng, Laura Laidler, Lina Albitar, Anna Holmes, Donghai Dai, Thomas Buekers, David Bender, Kimberly Leslie
Xiangbing Meng
Serous uterine endometrial cancer is a lethal disease for which new therapeutic regimens are urgently needed. Combinations of chemotherapeutic agents and small molecule growth factor inhibitors have demonstrated activity in cancers from other sites. Our objective was to determine whether such a combination using Paclitaxel and Gefitinib could be active in serous endometrial cancer cells.